As of December 18, 2023**, the Shanghai Composite Index closed down 040% at 293080 o'clock;The Shenzhen Component Index closed down 113% at 927939 o'clock;The GEM index closed down 154% at 1820At 00 o'clock, the effect of losing money in the day was amplified. The total turnover of the two cities is 69264.5 billion yuan.
The CSI Medical and Health Index (000933) closed up 014%, and the constituent stock Yirui Technology (688301) closed up 595%, Tasly (600535) closed up 441%, and new industries (300832) closed up 414%, Shenzhou Cell (688520) closed up 307%, Tiantan Biology (600161) closed up 235%。Pharmaceutical ETF (159929) long and short stalemate, the latest**144 yuan, ** turnover of 5588210,000 yuan.
In terms of scale, the latest scale of pharmaceutical ETFs has reached 190.9 billion yuan.
The data shows that leveraged funds continue to be deployed. The net inflow of funds in the pharmaceutical ETF on the last trading day was 4.36 million yuan, and the latest financing amount reached 357540,000 yuan, the latest financing balance reached 6505710,000 yuan, a new high.
From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI Healthcare Index tracked by the pharmaceutical ETF is only 2566 times, at 9 in the last 3 yearsThe quantile of 59%, that is, the valuation is lower than 90 in the last 3 yearsMore than 41% of the time, at historical lows.
In order to reflect the overall performance of companies in different industries in the CSI 800 Index sample** and provide investors with an analytical tool, the CSI 800 Index sample is divided into 11 primary industries and 35 secondary industries according to the CSI Industry Classification.
All ** of the primary and secondary industries are used as samples to compile the index to form the CSI 800 industry index.
According to the data, as of November 30, 2023, the top ten weighted stocks in the CSI Medical and Health Index (000933) are Hengrui Pharmaceutical (600276), WuXi AppTec (603259), Mindray Medical (300760), Aier Ophthalmology (300015), Zhifei Biotechnology (300122), Pien Tze Huang (600436), Changchun High-tech (000661), Watson Biotechnology (300142), Shanghai RAAS (002252), and Tongrentang(600085), the top 10 weighted stocks accounted for 4517%。
Zhongtai ** said: During the current performance window period, medicine is expected to continue to bloom in more places, and the bottom is expected to continue to be favored by funds, and at the same time, the high quality of the early stage will also bring a better layout opportunity. Under the trend of rigid demand and aging, we are firmly optimistic about the investment opportunities in the pharmaceutical sector, and 2024 is expected to be the first year of start-up.
Pharmaceutical ETF (159929), OTC Feeder (Class A: 007076;Category C: 007077).
The content and data are for reference only and do not constitute investment advice. AI technology strategy is provided for Youlian Cloud.